Our results extend the regulation of miR-21 by STAT5 to CML, where the role of this transcription factor seems essential, since 2-nt mutations in the binding sites significantly and strongly reduce the activity of the miR-21 promoter. The gene discussed is STAT5A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.